HopeStage
Back to all studies
CompletedNCT03056482

Haloperidol Compared With Ondansetron for Cannabis-Related Vomiting

About this titleRead the official source — NCT03056482
Medication studyAges 18–100CanadaAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 100 years.

Listed locations
Kingston and 2 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 21, 2017
Recruitment status
Completed
Enrollment listed in the registry
33
Sponsor
Dr. Marco L.A. Sivilotti
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
From 18 Years to 100 Years
Official registry ID
NCT03056482
Official title
Show the full official title

Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Kingston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Dr. Marco L.A. Sivilotti.

Did this study involve medication?

Yes. The study involved medication, including Ondansetron 8mg, Haloperidol 0.05mg/kg and Haloperidol 0.1mg/kg.

Who was this study for?

Listed age limits: 18 years to 100 years.

Want to explore more studies?

Explore studies